CN113552347A - Application of reagent for detecting follicular regulatory T cells in preparation of diagnostic reagent for prognosis of immunotherapy of allergic rhinitis - Google Patents
Application of reagent for detecting follicular regulatory T cells in preparation of diagnostic reagent for prognosis of immunotherapy of allergic rhinitis Download PDFInfo
- Publication number
- CN113552347A CN113552347A CN202110809036.4A CN202110809036A CN113552347A CN 113552347 A CN113552347 A CN 113552347A CN 202110809036 A CN202110809036 A CN 202110809036A CN 113552347 A CN113552347 A CN 113552347A
- Authority
- CN
- China
- Prior art keywords
- cells
- allergic rhinitis
- reagent
- immunotherapy
- follicular regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 76
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 76
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract description 53
- 108010046926 intraovarian peptides Proteins 0.000 title claims abstract description 52
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 35
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 32
- 238000004393 prognosis Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000001514 detection method Methods 0.000 claims abstract description 6
- 238000000684 flow cytometry Methods 0.000 claims abstract description 5
- 238000003745 diagnosis Methods 0.000 claims abstract description 4
- 210000005087 mononuclear cell Anatomy 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 230000010100 anticoagulation Effects 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 230000002596 correlated effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 4
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 239000008055 phosphate buffer solution Substances 0.000 claims 3
- 238000005119 centrifugation Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000003550 marker Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000090 biomarker Substances 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- 210000001944 turbinate Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 108700010013 HMGB1 Proteins 0.000 description 4
- 102100037907 High mobility group protein B1 Human genes 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 210000002850 nasal mucosa Anatomy 0.000 description 4
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 3
- 101150021904 HMGB1 gene Proteins 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000057955 Eosinophil Cationic Human genes 0.000 description 1
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000055207 HMGB1 Human genes 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940124829 interleukin-23 Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/14—Disorders of ear, nose or throat
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses an application of a reagent for detecting follicular regulatory T cells in preparation of an allergic rhinitis immunotherapy prognosis diagnosis reagent, and belongs to the technical field of allergic rhinitis detection. Specifically, the method comprises the following steps: 1) preparing peripheral blood mononuclear cells; 2) measuring the expression level of the follicular regulatory T cells in the mononuclear cells of step 1) by flow cytometry. The invention judges the severity of the allergic rhinitis by detecting the level of follicular regulatory T cells in the peripheral blood mononuclear cells of a normal sample and a patient with the allergic rhinitis, and provides an important basis for the disease risk and treatment scheme of the patient with the allergic rhinitis; meanwhile, the level of follicular regulatory T cells in peripheral blood mononuclear cells of a patient with allergic rhinitis before and after receiving immunotherapy is monitored, so that the prognosis index of the allergic rhinitis immunotherapy is judged.
Description
Technical Field
The invention relates to application of a follicular regulatory T cell as an allergic rhinitis marker in judging the prognosis of immunotherapy of an allergic rhinitis patient, belongs to the technical field of allergic rhinitis detection, and particularly relates to application of a reagent for detecting follicular regulatory T cells in preparing an allergic rhinitis immunotherapy prognosis diagnosis reagent.
Background
Allergic Rhinitis (AR) refers to a nasal mucosa non-infectious chronic inflammatory disease mainly mediated by IgE after an organism is exposed to an allergen, and the prevalence rate of AR in continental areas of China is 4-38%. The main symptoms of AR include nasal itching, sneezing, watery nasal discharge, itchy eyes, nasal congestion, etc., which affect the life, sleep, and work quality of patients and cause serious social and economic burden. Current treatment regimens for AR include allergen avoidance, medication, AIT (allergen-specific immunotherapy) and patient education. Unlike temporary relief of symptoms by avoiding exposure to allergens and medications, the allergen extract (vaccine) in AIT induces immune tolerance in the body by repeated exposure to the patient and increasing the dose gradually, thereby controlling or alleviating allergic symptoms. However, AIT also has the disadvantages of long treatment period, high cost, poor patient compliance, and susceptibility to serious complications. More importantly, a considerable part of patients with allergic rhinitis do not respond well to AIT, and a great deal of waste of social and medical resources and individual economic loss are caused. Therefore, the search for biomarkers that can monitor and predict the efficacy of AIT, and the search for new methods that can enhance the efficacy of AIT, are the key and difficult points of research on allergic rhinitis and AIT.
The document "application of biomarkers in the evaluation of the efficacy of specific immunotherapy for allergic rhinitis" mentions that some potential indexes related to the occurrence and diagnosis and treatment of allergic rhinitis, such as specific IgE, interleukin 2(IL-2), IL-4, IL-5, eosinophil cationic protein, eosinophil, specific IgG4, interferon gamma, regulatory T cells, sIgE/tIgE ratio, etc., have been found at home and abroad at present. As reported in the literature, "expression and significance of interleukin 23 in nasal mucosa of patients with allergic rhinitis", the expression of 1L-23 in the lower nasal mucosa of 12 cases of AR patients (AR group) and 11 cases of simple nasal septum deflection patients (control group) were collected and detected by immunohistochemistry and quantitative RT-PCR. The results show that the expression level of 1L-23P19mRNA in the AR group is obviously improved compared with the control group (P is less than 0.01). Immunohistochemistry shows that the 1L-23 protein is mainly expressed in inflammatory infiltration cells of a mucous membrane lamina propria, and the number of 1L-23 positive cells in the nasal mucosa of the AR group is obviously higher than that of a control group (P is less than 0.01). The expression levels of 1L-23P19mRNA and protein are obviously and positively correlated with the infiltration degree of total inflammatory cells of the mucous lamina propria and the deposition degree of collagen fibers of the lamina propria (the correlation coefficients are 0.678 and 0.834 respectively for the expression level of mRNA, and 0.644 and 0.721 respectively for the expression level of protein, and the P is less than 0.01). And the literature, "expression and significance of high-mobility group protein B1 in allergic rhinitis" describes that the expression of HMGB1 in the inferior turbinate mucosa of 12 patients with allergic rhinitis and the expression of HMGB1 in the inferior turbinate mucosa of 11 patients with simple nasal septum deflection (a control group) are collected and detected by adopting immunohistochemistry and RT-PCR (reverse transcription-polymerase chain reaction) methods, and the result shows that the expression level of the HMGB1 in the inferior turbinate mucosa of the patients with allergic rhinitis is obviously higher than that in the control group (P is less than 0.01). Immunohistochemistry shows that positive expression is mainly located in the mesentery of the mucosa, the fluorescence intensity in the mucosa of the turbinate of patients with allergic rhinitis is obviously higher than that of a control group (P < 0.01), the HMGB1mRNA level (5.0 +/-1.2) and the protein level are both positively correlated with the number of mature dendritic cells in the mucosa of the turbinate (r ═ 0.695, r ═ 0.578, P < 0.01), and the HMGB1 protein level and the eosinophil cell number (40.0 +/-3.1) in the mucosa of the turbinate are obviously negatively correlated (r ═ 0.547, P < 0.01).
The search for new markers of allergic rhinitis and the possibility of specific assessment of clinical efficacy is the current focus of research.
Disclosure of Invention
In order to solve the technical problems, the invention discloses an application of a reagent for detecting follicular regulatory T cells in preparation of an allergic rhinitis immunotherapy prognosis diagnostic reagent. The follicular regulatory T cells can be used as an effective marker of allergic rhinitis, can be used for judging the severity of diseases, and can provide basis and related guidance for the disease risk and treatment scheme of patients.
In order to achieve the purpose, the invention discloses an application of a reagent for detecting follicular regulatory T cells in preparing an allergic rhinitis immunotherapy prognosis diagnostic reagent.
Further, it comprises measuring the level of follicular regulatory T cells in peripheral blood mononuclear cells from normal samples and patients with allergic rhinitis in vitro.
Further, it comprises monitoring the level of follicular regulatory T cells in peripheral blood mononuclear cells of patients with allergic rhinitis before and after receiving immunotherapy.
Further, by monitoring changes in and correlation of follicular regulatory T cell expression levels, the number of follicular regulatory T cells in the peripheral blood mononuclear cells is increased compared to before treatment.
Further, the expression level of the follicular regulatory T cells in peripheral blood mononuclear cells of patients with allergic rhinitis is clearly correlated with the severity of allergic rhinitis, and the correlation coefficient r is-0.206, which indicates that the severity of allergic rhinitis is closely related to the expression level of the follicular regulatory T cells in peripheral blood mononuclear cells.
Further, it comprises the following detection steps:
1) preparing peripheral blood mononuclear cells;
2) detecting the expression level of follicular regulatory T cells in said mononuclear cells of step 1) by flow cytometry.
Further, the specific process of step 1) is as follows:
1.1) taking a peripheral blood lymphocyte separation solution and placing the separation solution at the bottom of a test tube;
1.2) preparing an anticoagulant diluent: placing the vein anticoagulation blood at the bottom of another test tube, and adding PBS with the same volume to dilute;
1.3) premixing: slowly adding the anticoagulation diluent in the step 1.2) into the peripheral blood lymphocyte separation solution in the step 1.1);
1.4) centrifugal treatment;
1.5) preparation of suspension cells: and (3) taking out an interface white cell layer of the solution formed after the centrifugal treatment in the step 1.4), adding PBS for dilution, and suspending the cells.
Further, in the step 1.2), the venous anticoagulation is that 15-25 units of heparin is added into each milliliter of blood.
Further, in step 1.4), the centrifugal processing conditions are as follows: at room temperature, the centrifugal speed is 1800-2200 r/min, and the centrifugal treatment is 15-25 min.
In addition, the invention also discloses a diagnostic kit for the prognosis of allergic rhinitis, which comprises the application. Meanwhile, the diagnostic kit comprises a substance for detecting the level of follicular regulatory T cells in peripheral blood mononuclear cells, as shown in any one of the following tables. Namely, any one or two or more of CD3 antibody, CD4 antibody, CD45RA antibody, CXCR5 antibody, CD127 antibody and CD25 antibody, and all antibodies are fluorescently labeled antibodies.
Has the advantages that:
1. the invention judges the severity of the allergic rhinitis by detecting the level of follicular regulatory T cells in the normal sample and peripheral blood mononuclear cells of the patient with the allergic rhinitis, and provides an important basis for the disease risk and treatment scheme of the patient with the allergic rhinitis.
2. The invention judges the allergic rhinitis immunotherapy prognosis index by monitoring the level of follicular regulatory T cells in peripheral blood mononuclear cells of a patient with allergic rhinitis before and after receiving immunotherapy.
3. The invention adopts the follicular regulatory T cells in the peripheral blood mononuclear cells as the allergic rhinitis prognosis diagnostic reagent, and the detection process is convenient and rapid.
Drawings
FIG. 1 is a schematic representation of a study of the correlation of follicular regulatory T cells with allergic rhinitis;
FIG. 2 is a schematic representation of the study of the correlation of follicular regulatory T cells with allergic rhinitis;
FIG. 3 is a schematic representation of a study of follicular regulatory T cell levels in peripheral blood mononuclear cells of patients with allergic rhinitis before and after receiving immunotherapy;
FIG. 4 is a schematic representation of the study of follicular regulatory T cells levels in peripheral blood mononuclear cells before and after receiving immunotherapy in patients with allergic rhinitis.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Definition and use of terms
As used herein, the term "and/or" means any one of the options or two or more of the options.
The term "marker" or "biomarker" is an organic biomolecule that is differentially present in a sample taken from a subject of one phenotypic state (e.g., having a disease) as compared to another phenotypic state (e.g., not having a disease). Biomarkers differ in different phenotypic states if the average or median level of the biomarker, e.g., expression level, in different groups is calculated to be statistically significant.
The term "sample" as used herein refers to a collection of similar cells or tissues isolated from a subject, as well as tissues, cells, and fluids present within a subject. The term "sample" includes any bodily fluid (e.g., blood, lymph, gynecological fluid, cystic fluid, urine, tears, and fluid collected by bronchial lavage and/or peritoneal irrigation) or cell from a subject. In one embodiment, the tissue or cell is removed from the subject. In another embodiment, the cell is present in the subject. Other subject samples include tear drops, serum, cerebrospinal fluid, feces, sputum, and cell extracts. In one embodiment, the biological sample comprises a protein molecule from a test subject. In another embodiment, the biological sample may comprise mRNA molecules from a test subject or genomic DNA molecules from a test subject.
The term "determining" is intended to include methods of detecting the presence or absence of a marker in a sample, quantitatively determining the amount of a marker in a sample, and/or determining the type of biomarker.
The term "monitoring" means a method that is capable of knowing in real time the presence or absence of a marker in a test sample, quantitatively determining the amount of a marker in a sample, and/or determining the type of biomarker.
The term "kit" is any article of manufacture (e.g., package or container) comprising at least one reagent, e.g., probe, primer or antibody, that specifically detects a marker of the invention, which article of manufacture is promoted, distributed or sold as one unit for performing a method of the invention. In certain embodiments, a kit can include a substrate, e.g., a substrate comprising a capture reagent of one or more markers of the invention and/or a capture reagent bound to one or more markers of the invention. In some embodiments, such kits comprise instructions for determining the level of the marker using mass spectrometry.
Subjects or patients may include, but are not limited to, mammals, such as cows, birds, dogs, horses, cats, sheep, pigs, or primates (including humans and non-primates).
Example 1: judging the severity of allergic rhinitis of a patient by detecting the expression level of follicular regulatory T cells
Experimental subject and materials:
1. subject:
peripheral blood samples from allergic rhinitis patients and normal controls were obtained from multi-market hospitals in Wuhan City. Morning fasting anticoagulation.
2. Experimental materials:
1. antibody: as in table 1 below;
TABLE 1 list of antibody compositions
2. Other materials:
(1) FACS buffer: 3% calf serum in PBS;
(2) conical tubes (BD Labware);
(3)PBS；
3. instrument for measuring the position of a moving object
BD LSRFortessaTMX-20 flow cytometry;
3. specific experiments are as follows:
(1) and (5) harvesting the single cell suspension of the peripheral blood.
(2) Cells were transferred to 50mL conical tubes and centrifuged at 300RCF for 5min at 4 ℃.
(3) The supernatant was discarded and the precipitate was retained.
(4) Cells were resuspended in PBS and kept on ice for 5 min.
(5) Then, 15mL of PBS and 300RCF were added, and the mixture was centrifuged at 4 ℃ for 5 min.
(6) The supernatant was discarded, 20mL of PBS was added to resuspend the cells, and the cells were counted.
(7) 5% calf serum was added to 50uL of cell suspension for blocking and incubation on ice for 10 min.
(8) Cells were washed with 200mL PBS, centrifuged at 300RCF at 4 ℃ for 5 min.
(9) The supernatant was discarded, and the cells were resuspended with 30uL each of fluorescently labeled CD3, CD4, CD45RA, CXCR5, CD127 and CD25 antibodies or isotype (1: 50in FACS buffer), and incubated on ice for 30 min.
(10) Cells were washed 3 times with 200mL PBS, centrifuged at 300RCF at 4 ℃ for 5 min.
(11) The cells were resuspended at 400uLPBS and analyzed by BD LSRFortessaTmX-20 flow cytometry, and the follicular regulatory T cells were labeled CD3+ CD4+ CD45RAlowCXCR5+ CD25highCD127 low.
4. The experimental results are as follows:
as can be seen from fig. 1 and 2, the level of follicular regulatory T cells in patients with allergic rhinitis was significantly lower than in normal persons. By correlation, the severity of allergic rhinitis can be judged by detecting the level of follicular regulatory T cells.
Example 2: judging allergic rhinitis immunotherapy prognostic index by monitoring the change of expression level of follicular regulatory T cells in peripheral blood mononuclear cells of patients with allergic rhinitis before and after receiving immunotherapy
Experimental subject and materials:
1. subject:
peripheral blood samples from patients with allergic rhinitis and from multi-market hospitals in Wuhan City were obtained from the same patients after receiving immunotherapy. The immunotherapy method for allergic rhinitis patients of the present application is subcutaneous injection.
2. Experimental materials:
the same as in example 1.
3. The experimental method comprises the following steps:
the same as in example 1.
4. The experimental results are as follows:
as can be seen from fig. 3, when the patients with allergic rhinitis received specific immunotherapy, the level of follicular regulatory T cells was significantly increased, and as can be seen from fig. 4, the clinical score of the patients was also significantly decreased, which was clearly inversely correlated with that of follicular regulatory T cells.
Example 3
The application also discloses a diagnostic reagent for the prognosis of allergic rhinitis, which comprises a substance for detecting the level of follicular regulatory T cells in peripheral blood mononuclear cells, and comprises an antibody composition for detecting follicular regulatory T cells in peripheral blood mononuclear cells, wherein the antibody composition comprises any one or two or more of a CD3 antibody, a CD4 antibody, a CD45RA antibody, a CXCR5 antibody, a CD127 antibody and a CD25 antibody, and all the antibodies are fluorescently labeled antibodies. Specifically, as shown in table 1 above.
Therefore, the diagnostic kit designed by the invention can effectively monitor the expression level of follicular regulatory T cells in peripheral blood mononuclear cells of patients with allergic rhinitis in the prognosis and the prognosis, and provides important guiding significance for predicting the AIT curative effect and searching a new AIT treatment method.
In addition, the diagnostic kit designed by the invention can also cooperate with other detection indexes.
The present invention is not limited to the above-described alternative embodiments, and various other forms of products can be obtained by anyone in light of the present invention. The above detailed description should not be taken as limiting the scope of the invention, which is defined in the claims, and which the description is intended to be interpreted accordingly.
Claims (10)
1. An application of a reagent for detecting follicular regulatory T cells in preparing an immune therapy prognosis diagnostic reagent for allergic rhinitis.
2. The use of the follicular regulatory T cell reagent of claim 1 for the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, comprising the step of measuring the level of follicular regulatory T cells in a normal in vitro sample and peripheral blood mononuclear cells of a patient with allergic rhinitis.
3. The use of the follicular regulatory T cell reagent of claim 2 for the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, further comprising monitoring the level of follicular regulatory T cells in peripheral blood mononuclear cells of a patient with allergic rhinitis before and after receiving immunotherapy.
4. Use of the follicular regulatory T cell reagent of claim 3 for the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, wherein the number of follicular regulatory T cells in said peripheral blood mononuclear cells is increased compared to the number before treatment by monitoring changes and correlations in the expression level of follicular regulatory T cells.
5. The use of the reagent for detecting follicular regulatory T cells according to any one of claims 1 to 4, in the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, wherein the expression level of follicular regulatory T cells in peripheral blood mononuclear cells of patients with allergic rhinitis is significantly correlated with the severity of allergic rhinitis, and the correlation coefficient r is-0.206.
6. The use of the reagent for detecting follicular regulatory T cells according to any one of claims 1 to 4 for the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, comprising the following detection steps:
1) preparing peripheral blood mononuclear cells;
2) detecting the expression level of follicular regulatory T cells in said mononuclear cells of step 1) by flow cytometry.
7. The use of the reagent for detecting follicular regulatory T cells as defined in claim 6 for the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, wherein the specific process of step 1) is as follows:
1.1) taking a peripheral blood lymphocyte separation solution and placing the separation solution at the bottom of a test tube;
1.2) preparing an anticoagulant diluent: placing the vein anticoagulation blood at the bottom of another test tube, and adding PBS with the same volume to dilute;
1.3) premixing: slowly adding the anticoagulation diluent in the step 1.2) into the peripheral blood lymphocyte separation solution in the step 1.1);
1.4) centrifugal treatment;
1.5) preparation of suspension cells: and (3) taking out the interface white cell layer of the solution formed after the centrifugal treatment in the step 1.4), and adding PBS (phosphate buffer solution) for dilution to obtain the suspension cells.
8. The use of the reagent for detecting follicular regulatory T cells according to claim 7 for the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, wherein in step 1.2), said venous anticoagulation is 15-25 units per ml of blood heparin.
9. The use of the reagent for detecting follicular regulatory T cells as defined in claim 7 for the preparation of a prognostic diagnostic reagent for immunotherapy of allergic rhinitis, wherein in step 1.4), the centrifugation conditions are: at room temperature, the centrifugal speed is 1800-2200 r/min, and the centrifugal treatment is 15-25 min.
10. An allergic rhinitis immunotherapy prognosis diagnosis kit, characterized in that it comprises an antibody composition for detecting follicular regulatory T cells in peripheral blood mononuclear cells, said antibody composition comprising any one or two or more of a CD3 antibody, a CD4 antibody, a CD45RA antibody, a CXCR5 antibody, a CD127 antibody and a CD25 antibody, and all the antibodies are fluorescently labeled antibodies.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110809036.4A CN113552347A (en) | 2021-07-16 | 2021-07-16 | Application of reagent for detecting follicular regulatory T cells in preparation of diagnostic reagent for prognosis of immunotherapy of allergic rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110809036.4A CN113552347A (en) | 2021-07-16 | 2021-07-16 | Application of reagent for detecting follicular regulatory T cells in preparation of diagnostic reagent for prognosis of immunotherapy of allergic rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113552347A true CN113552347A (en) | 2021-10-26 |
Family
ID=78103292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110809036.4A Pending CN113552347A (en) | 2021-07-16 | 2021-07-16 | Application of reagent for detecting follicular regulatory T cells in preparation of diagnostic reagent for prognosis of immunotherapy of allergic rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113552347A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671140A (en) * | 2022-10-31 | 2023-02-03 | 华中科技大学同济医学院附属同济医院 | Application of propionibacterium acnes in preparation of medicine for treating nasal polyp |
| CN115792229A (en) * | 2022-01-28 | 2023-03-14 | 华中科技大学同济医学院附属同济医院 | Application of tPA in nasal secretion in preparation of nasal polyp and prognosis detection agent thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006275302A1 (en) * | 2005-08-02 | 2007-02-08 | Centenary Institute Of Cancer Medicine And Cell Biology | Method for identifying regulatory T cells |
| CN103782173A (en) * | 2011-07-01 | 2014-05-07 | 贝克曼考尔特公司 | Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders |
| CN108982339A (en) * | 2018-09-12 | 2018-12-11 | 李小峰 | A kind of peripheral blood folliculus regulatory T cells concentration detection method |
| WO2018224506A2 (en) * | 2017-06-06 | 2018-12-13 | Instituto De Medicina Molecular | Auto immune diagnosis using t cell populations |
| EP3418738A1 (en) * | 2017-06-23 | 2018-12-26 | Klinikum rechts der Isar der Technischen Universität München | A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy |
-
2021
- 2021-07-16 CN CN202110809036.4A patent/CN113552347A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006275302A1 (en) * | 2005-08-02 | 2007-02-08 | Centenary Institute Of Cancer Medicine And Cell Biology | Method for identifying regulatory T cells |
| CN103782173A (en) * | 2011-07-01 | 2014-05-07 | 贝克曼考尔特公司 | Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders |
| WO2018224506A2 (en) * | 2017-06-06 | 2018-12-13 | Instituto De Medicina Molecular | Auto immune diagnosis using t cell populations |
| EP3418738A1 (en) * | 2017-06-23 | 2018-12-26 | Klinikum rechts der Isar der Technischen Universität München | A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy |
| CN108982339A (en) * | 2018-09-12 | 2018-12-11 | 李小峰 | A kind of peripheral blood folliculus regulatory T cells concentration detection method |
Non-Patent Citations (1)
| Title |
|---|
| YIN YAO, MD等: "Allergen immunotherapy improves defective follicular regulatory T cells in patients with allergic rhinitis", J ALLERGY CLIN IMMUNOL, pages 1 - 3 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115792229A (en) * | 2022-01-28 | 2023-03-14 | 华中科技大学同济医学院附属同济医院 | Application of tPA in nasal secretion in preparation of nasal polyp and prognosis detection agent thereof |
| CN115671140A (en) * | 2022-10-31 | 2023-02-03 | 华中科技大学同济医学院附属同济医院 | Application of propionibacterium acnes in preparation of medicine for treating nasal polyp |
| CN115671140B (en) * | 2022-10-31 | 2024-03-22 | 华中科技大学同济医学院附属同济医院 | Application of propionibacterium acnes in preparation of medicines for treating nasal polyp |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Th17 and natural Treg cell population dynamics in systemic lupus erythematosus | |
| WO2013066369A2 (en) | Methods for detecting graft-versus-host disease | |
| Wong et al. | Aberrant expression of regulatory cytokine IL-35 and pattern recognition receptor NOD2 in patients with allergic asthma | |
| CN113552347A (en) | Application of reagent for detecting follicular regulatory T cells in preparation of diagnostic reagent for prognosis of immunotherapy of allergic rhinitis | |
| CN104040349A (en) | Methods for monitoring responsiveness to anti-SMAD7 therapy | |
| EP2856171A1 (en) | Methods for diagnosing osteoarthritis | |
| Liu et al. | Elevated interleukin-18 and skewed Th1: Th2 immune response in lupus nephritis | |
| Aljadi et al. | A novel tool for clinical diagnosis of allergy operating a microfluidic immunoaffinity basophil activation test technique | |
| US20200011865A1 (en) | Methods and kits for detecting basophil activation | |
| Furuzawa-Carballeda et al. | Indoleamine 2, 3‐Dioxygenase: Expressing Cells in Inflammatory Bowel Disease—A Cross‐Sectional Study | |
| CN109991417B (en) | Immune marker for tuberculosis and application | |
| RU2672595C2 (en) | Method for diagnosing molecular phenotype of patients suffering from diseases accompanied by chronic inflammation | |
| Mohsen et al. | Serum interleukin-18 levels in patients with systemic lupus erythematosus: relation with disease activity and lupus nephritis | |
| WO2016161413A1 (en) | Urinary tract infection biomarkers | |
| Mouthuy et al. | Mite allergen–specific IgE is detectable in bronchial secretions of patients with nonatopic asthma and correlates with mucosal expression of periostin | |
| JP6628178B2 (en) | Method for testing IgE-independent allergic disease | |
| RU2694223C1 (en) | Method for prediction of the risk of infectious complications in atopic dermatitis | |
| Hashad et al. | Interleukins 12 and 13 levels among beta-thalassaemia major patients | |
| US20220128572A1 (en) | Immunological signatures and parameters predicting therapeutic responses to anti-tnf therapy | |
| Siddhuraj et al. | Histology-based blood leukocyte profiling reveals parallel Th2 and Th17 signatures in seasonal allergic rhinitis | |
| CN111575385B (en) | Application of SB290157 in ovarian epithelial cancer diseases | |
| WO2023046111A1 (en) | Basophil activation detection method and application thereof | |
| Nuswantoro et al. | Evaluation of Haemoglobin, Total Leukocytes, and Neutrophil/Lymphocyte Ratio as A Predictors of C-Reactive Protein Levels in Patients with Pulmonary Tuberculosis from Pontianak, West Kalimantan. | |
| Arlt et al. | An unbiased approach of individual tissue-specific autoantibody identification using Immunoprecipitation coupled to Mass-Spectrometry (IP-MS) | |
| CN116482390A (en) | Application of Apo-AI detection reagent in evaluating therapeutic effect of allergic rhinitis immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |